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Abstract
Background: Portal vein embolization (PVE) is used before extensive hepatic resections to increase
the volume of the future remnant liver within acceptable safety margins (conventionally >0.6% of the
patient’s weight). The objective was to determine whether pre-operative PVE impacts on post-opera-
tive liver function independently from the increase in liver volume.
Methods: The post-operative liver function of patients who underwent an anatomical right liver resec-
tion with (n = 28) and without (n = 53) PVE were retrospectively analysed. Donors of the right liver were
also analysed (LD) (n = 17).
Results: Patient characteristics were similar, except for age, weight and American Society of Anesthe-
siologists (ASA) score that were lower in LD. Post-operative factor V and bilirubin levels were, respec-
tively, higher and lower in patients with PVE compared with patients without PVE or LD (P < 0.05).
Patients with PVE had an increased blood loss, blood transfusions and sinusoidal obstruction syn-
drome. The day-3 bilirubin level was 40% lower in the PVE group compared with the no-PVE group
after adjustment for body weight, chemotherapy, operating time, Pringle time, blood transfusions,
remnant liver volume, pre-operative bilirubin level and pre-operative prothrombin ratio (P = 0.001).
Conclusions: For equivalent volumes, the immediate post-operative hepatic function appears to be
better in livers prepared with PVE than in unprepared livers. Future studies should analyse whether the
conventional inferior volume limit that allows a safe liver resection may be lowered when a PVE is per-
formed.
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Introduction
Over the past two decades, pre-operative portal vein emboliza-
tion (PVE) has emerged as an effective way to increase the vol-
ume of the future remnant liver in patients undergoing major
liver resections. PVE interrupts the blood supply of the portal
territories to be resected, thus inducing a compensatory hyper-
trophy of the future remnant liver. This increase in the volume
of healthy parenchyma is crucial for many patients, allowing
surgery to be performed. Conventionally, a future remnant
liver volume of 0.6% of the patient’s weight or 25–30% of the
total liver volume is considered safe for a liver resection.1 In
case of underlying parenchymal disease (i.e. cirrhosis, steatosis,
or post chemotherapy liver damage2), the safe cut-off rises up
to or beyond 1% of the patient’s weight or 40% of the total
liver volume.3,4 The current practice requires that a sufficient
This study was presented at the Annual Meeting of the Swiss Society of
Gastroenterology and Visceral Surgery, 29–30 September 2011, Lausanne,
Switzerland.
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increase in liver volume be obtained for the patient to undergo
surgery. However, little is known on the impact of PVE on
liver function, and denying surgery to patients who did not
achieve a given liver volume may be inappropriate. A prospec-
tive clinical study suggested that after PVE, patients with the
chronic liver disease had less post-operative complications than
patients without PVE.5 Other clinical studies suggested that the
increase in future remnant liver function was more pro-
nounced than the increase in future remnant liver volume after
PVE, but none used a control group without PVE, nor esti-
mated the function of a given volume of liver tissue per unit
of patient’s weight.6–9
The aim of the present study was to test and quantify the
assumption that an increase in volume correlates with an
increase in function, and to analyse whether post-operative
liver function per unit of liver volume (i.e. specific liver func-
tion), rather than just volume, was increased by pre-operative
PVE. Besides the well-established fact that PVE increases the
chance of performing a large hepatic resection, here it is shown
that the liver is primed after PVE and that this results in an
increase in function per unit of liver volume.
Patients and methods
Patients
Five hundred and forty-nine patients underwent liver resec-
tions at Geneva University Hospitals between 1999 and 2010.
Patients who underwent an anatomical right liver resection
(segments 5–8, in some patients extended to segment 1 and
4) were identified. To homogenize the cohort, patients older
than 70 years, with cirrhosis, with a Pringle manoeuvre
exceeding a total of 40 min, with simultaneous left liver resec-
tions, or with pre-operative chronic cholestasis were excluded
from the study. A detailed flow chart is available in Fig. S1.
Exclusion according to these criteria left 28 patients who had
pre-operative PVE (study group), 70 patients who had no
PVE (53 curative right hepatectomy; control group 1) and 17
liver donors (LD) for adult-to-adult living donor transplanta-
tion (right liver grafts; control group 2). An institution’s
Computerized Patient Record System was used; a retrospective
analysis of prospectively backed up laboratory data, proce-
dures, hospital course and a digitized computed tomography
(CT) scan was conducted for every patient. The study was
approved by the local research ethics committee of the
Departments of Surgery of Geneva University Hospitals (pro-
tocol NAC 10-158R).
Portal vein embolization
Percutaneous embolization of the right portal vein and its
intrahepatic branches was performed under general anaesthesia,
using an ipsilateral (n = 9) or contralateral (n = 19) approach.
The portal system was punctured with a 22-G Chiba needle
under ultrasound guidance. After catheterization with a 5-F
catheter, the targeted segmental portal veins were successively
embolized under fluoroscopic guidance, using a 1:1 mixture of
n-butyl-cyanoacrylate (Histoacryl) and iodized oil (Lipi-
odol). In three patients embolization also involved segment 4
and was performed with ethylene-vinyl alcohol copolymer
(Onyx) through a 2.4-F micro catheter. PVE was performed
in patients with an estimated future remnant liver of less than
30% of the functional liver mass (or 40% after extensive
neoadjuvant chemotherapy).10 The waiting time from PVE to
resection was 6 weeks for every patient.
Liver resection
A right or extended right hepatectomy was performed using a
standardized technique.10 Briefly, after exposure of the opera-
tive field through a subcostal approach, the liver was fully
mobilized, and the hepatic pedicle prepared. A liver parenchy-
mal transection was performed using the ultrasonic scalpel
(cavitational ultrasonic surgical aspiration) the monopolar,
bipolar and argon-beam coagulators, metal clips and ligatures.
Clamping of the hepatic pedicle was used parsimoniously.
Intra-operative ultrasound was used in every patient.
Liver histology
In patients with a curative hepatectomy, histopathology was
assessed on the resected liver. Pre-operative liver biopsies
were available for all living donors. Histological slides were
analysed by a specialized liver pathologist. Steatosis was
graded as follows: none, mild (involving <30% of the hepato-
cytes), moderate (involving 30–60% of the hepatocytes) and
severe (involving >60% of the hepatocytes).11 Parenchymal
abnormalities such as nodular regenerative hyperplasia or
sinusoidal obstruction syndrome (SOS) were systematically
identified.2
Volumetric assessment
The computerized tomography volumetry was measured by
two experienced radiologists (S.T. and R.B.), blinded to group
assignment and outcomes, using an open-source viewing soft-
ware (OsiriX). The total liver volume was measured in both
groups on the portal phase images of a contrast-enhanced CT
(slice thickness, 1.0–3.0 mm; interval thickness, 0.75–2.0 mm).
This examination was performed within 1 week before surgery
(i.e. 5 weeks after a PVE) in the study group and within
4 weeks before living donor liver transplantation. The remnant
liver volume was calculated by subtracting the weight of the
resected liver from the total liver volume, after conversion
using the specific gravity of liver tissue (1.067).12 The remnant
liver volume to body weight ratio was calculated and was
expressed as a percentage of the body weight.
Laboratory data
Pre-(hereafter known as day 0) and post-operative total biliru-
bin, prothrombin ratio, factor V, aspartate transaminase (AST)
and alanine transaminase (ALT) levels were collected for every
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patient using computerized patient’s records. Pre-operative
factor V values were not systematically available; however, the
pre-operative prothrombin ratio was available for all patients.
When factor V reached 100%, it was not further dosed and
considered to stay at 100%.
Post-operative indices of liver function
To illustrate the capacity of a given amount of liver tissue to
metabolize bilirubin (i.e. a form of specific function of the liver),
an index integrating bilirubin at day 3, patient’s weight and
remnant liver volume was designed. Day-3 bilirubin was
chosen for its prognostic value, as reported in the literature.13
The index was:
Bilirubin at day 3 Patient0s weight
Remnant liver volume
To illustrate the above, the day-3 bilirubin levels are plotted
with the ratio between remnant liver volume and patient’s
weight for patients in all groups.
Statistical analysis
Continuous variables were expressed as means and standard
deviations (SD) and categorical variables were expressed as
percentages. Comparison between groups was performed using
the Mann–Whitney U-test. A linear regression model was used
to model the log of bilirubin concentration at day 3 for each
individual as a dependent variable. Independent variables
included: group (PVE or no PVE), body weight, chemotherapy,
operating time, Pringle time, blood transfusion, remnant liver
volume, pre-operative bilirubin level and the pre-operative
prothrombin ratio. Tests for the difference in the log of biliru-
bin concentration between groups were performed as likeli-
hood-ratio tests. Kaplan–Meier estimates were calculated using
the Gehan–Breslow–Wilcoxon Test. Statistical significance was
defined as P < 0.05.
Results
Baseline characteristics
Patient characteristics are summarized in Table 1. Compar-
ison between patients with and without PVE revealed no sig-
nificant difference in age, gender, weight, size and American
Society of Anesthesiologist physical status classification system
(ASA) score. As expected, comparison between patients with
PVE and liver donors showed that LD were younger, had a
lower weight and had a lower ASA score compared with
patients who underwent PVE and a right hepatectomy for a
disease.
Intra-operative course
Data regarding the intra-operative course are shown in
Table 2. Patients who underwent PVE had a longer operating
time lost more blood and were transfused more often com-
pared with patients without PVE. None of the patients received
fresh frozen plasma. In right liver donors, a short Pringle
manoeuvre was used only to determine the boundary of the
liver to be resected according to the vascularization of the par-
enchyma. The indication for surgery is listed in Table S1. Of
note, patients with cholangiocarcinoma had a biliary drainage
before surgery. Comparison between patients with PVE and
liver donors revealed that LD had a longer operating time, as
reported by others.14
Liver histopathology and chemotherapy
Data on liver histopathology and chemotherapy are presented
in Table 2. The prevalence of steatosis was not statistically dif-
ferent in the three groups. Patients with PVE had more often
SOS lesions associated with chemotherapy compared with
patients without PVE. The prevalence of Nodular Regenerative
Hyperplasia was not statistically different between patients with
and without PVE, and by definition LD had no chemotherapy-
associated lesions. The type of chemotherapy is listed in
Table S2.
Table 1 Characteristics of patients with and without portal vein embolization and liver donors
Variable PVE (n = 28) No PVE (n = 53) LD (n = 17) P-value* (PVE versus no PVE) P-value* (PVE versus LD)
Age (mean  SD) 55.7 (10.0) 53.7 (13.2) 38.4 (13.4) 0.812 <0.001
Gender (male) (%) 17 (60.7) 24 (45.3) 6 (35.3) 0.244 0.130
Weight (kg) (mean  SD) 74.1 (16.7) 69.5 (12.5) 65.7 (8.5) 0.229 0.050
Size (cm) (mean  SD) 170.1 (8.7) 168.9 (9.6) 168.5 (8.2) 0.319 0.493
ASA classification (%)
1 3 (10.7) 10 (18.9) 13 (76.5) 0.419 <0.001
2 22 (78.6) 38 (71.7) 4 (23.5)
3 3 (10.7) 5 (9.4) 0 (0.0)
4 0 (0.0) 0 (0.0) 0 (0.0)
PVE, portal vein embolization; LD, liver donor; ASA, American Society of Anesthesiologists physical status classification system; SD, standard
deviation.
*P-values were calculated using the Mann–Whitney U-Test (for continuous and categorical variables) or the Chi square test (for binary variables).
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Pre- and post-operative liver volumes
Comparisons of liver volumes are summarized in Table 3. No
significant difference in pre- and post-operative liver volumes
and volumes/body weight ratios was observed between the
PVE group and the no PVE group. Comparison between the
PVE group and LD showed that the total liver volume was lar-
ger in the PVE group; this difference was no longer present
when the liver volume was normalized to body weight. When
considering all patients together, the mean total liver volume
represented 2.3% of the body weight; the functional liver vol-
ume (calculated by subtracting the tumor volume to the total
liver volume) represented 2.1% of the body weight, and the
resected liver and remnant liver volume represented 1.2% each.
On average, patients had 54% of their initial functional liver
volume after the surgery. Overall, the measurement of pre-
and post-operative liver volumes normalized to patient’s
weight indicated that the extent of the right hepatectomy was
similar in the three groups.
Post-operative course after a right hepatectomy in
patients with and without pre-operative PVE and liver
donors
There was no post-operative mortality at 3 months. Specific
morbidity in the three groups was limited to Clavien’s grade
III complications15 (one late reoperation in a living donor for
a pleural empyema secondary to a bile leak). The analysis of
liver synthetic function showed that patients with PVE had
higher post-operative factor V values from day 1 to 4 com-
pared with patients without PVE and LD (Fig. 1a). The post-
operative prothrombin ratio confirmed differences observed in
factor V levels and were higher in patients with PVE from day
1 to 3 compared with the two other groups (Fig. 1b). The dif-
ferences were statistically significant at day 2 (Factor V and
prothrombin ratio), P ≤ 0.021 (PVE versus no PVE, and versus
LD). Patients with PVE had lower post-operative bilirubin val-
ues from day 1 to 7 compared with the two other groups
(Fig. 1c). The differences were statistically significant from day
1 to 4, P < 0.050 (PVE versus no PVE, and versus LD). Multi-
variate linear regression for factors influencing bilirubin levels
at day 3 (where the differences were the most important
between groups) showed that only Group (PVE versus no
PVE) had an impact on day-3 bilirubin value. On average, the
day-3 bilirubin value was 40% lower in patients with PVE
compared with the patients without PVE after adjustment for
body weight, chemotherapy, operating time, Pringle time,
blood transfusion, remnant liver volume, pre-operative biliru-
bin level and the pre-operative prothrombin ratio (P = 0.001)
(Table S3). None of the potential confounders was statistically
significant. Hepatic injury, as revealed by increases in ALT and
AST, was similar between the PVE group and the no PVE
group (Fig. 1d,e). The LD group had lower transaminases’
levels before (day 0) and after surgery (day 1) compared with
Table 2 Intra-operative course and liver histopathology in patients with and without portal vein embolization, and liver donors
Variable PVE (n = 28) No PVE (n = 53) LD (n = 17) P-value* (PVE versus
no PVE)
P-value*
(PVE versus LD)
Operating time (min) (mean  SD) 432.2 (69.2) 374.4 (88.9) 571.2 (89.8) 0.002 <0.001
Pringle time
None 22 (78.6) 47 (88.7) 15 (88.2) 0.228 0.360
<10 min 3 (10.7) 3 (5.7) 2 (11.8)
10–40 min 3 (10.7) 3 (5.7) 0 (0.0)
Blood loss (ml) (mean  SD) 892.5 (563.4) 566.7 (270.6) 559.1 (299.0) 0.041 0.079
Blood transfusion (RBC pack) (%)
0 18 (64.3) 46 (86.8) 11 (64.7) 0.019 0.762
1 4 (14.3) 3 (5.7) 5 (29.4)
2 6 (21.4) 4 (7.5) 0 (0.0)
3 0 (0) 0 (0) 1 (5.9)
Steatosis
None 10 (35.7) 15 (28.3) 8 (47.1) 0.463 0.284
Mild (<30%) 15 (53.6) 31 (58.5) 9 (52.9)
Moderate (30–60%) 3 (10.7) 4 (7.5) 0 (0)
Severe (>60%) 0 (0) 3 (5.7) 0 (0)
Sinusoidal obstruction syndrome (%) 14 (50.0) 12 (22.6) 0 (0.0) 0.015 <0.001
Nodular regenerative hyperplasia (%) 5 (17.9) 3 (5.7) 0 (0.0) 0.117 0.140
Chemotherapy (%) 22 (78.6) 31 (58.5) 0 (0.0) 0.088 <0.001
PVE, portal vein embolization; LD, liver donor; SD, standard deviation; RBC, red blood cell.
*P-values were calculated using the Mann–Whitney U-Test (for continuous and categorical variables) or the chi square test (for binary variables).
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the PVE group. Of note, patients with PVE had significantly
lower ALT and AST values 7 days after surgery, compared with
the two other groups (P ≤ 0.016).
Specific liver function index
To investigate the intrinsic metabolic capacity of a given
amount of liver tissue, an index of liver metabolic function
based on bilirubin values and taking into account the volume
of functional liver per kilo of body weight was modelled: Bilir-
ubin at day 3 9 Patient’s weight/Remnant Liver Volume.
Patients with PVE had significantly better index values as com-
pared with patients without PVE or LD (Fig. 2a). To illustrate
the index of liver metabolic function, the day-3 bilirubin value
was plotted against the residual liver volume/patient’s weight
ratio (Fig. 2b). A small residual liver volume and a high body
weight resulted in an increased day-3 bilirubin value in the
three groups. Overall, when considering patients with similar
residual liver volume and body weight, day-3 bilirubin was
lower in the PVE group compared with the no PVE group and
LD. The time to bilirubin normalization (i.e. ≤ 25 lmol/l) was
significantly shorter in patients who had PVE compared with
patients without PVE or LD (P ≤ 0.013) (Fig. 2c).
Discussion
PVE induces hepatocyte proliferation16–18 and increases the vol-
ume of the future remnant liver,19–21 with a favourable effect on
operability22–24 and on short- as well as long-term outcomes
after surgery.25–29 The aim of this study was to determine
whether pre-operative PVE had a positive impact on liver func-
tion (i.e. independently from the positive effect on liver volume)
in patients who underwent a major hepatectomy. Using two dif-
ferent control groups, pre-operative PVE was shown to increase
liver synthetic and metabolic functions in patients with similar
remnant liver volumes after a right hepatectomy.
The synthetic function of the liver, as assessed by factor V
activity and the prothrombin ratio, was markedly diminished
after a right hepatectomy. The decrease was dependent of the
volume of remnant liver normalized to body weight. In
patients with pre-operative PVE, the postoperative drop in
synthetic function was significantly less important. These
results were consistent with differences observed in liver meta-
bolic function between groups; liver primed with PVE required
a shorter time to serum bilirubin normalization than unpre-
pared liver.
One of the strengths of this study is that the pre- and post-op-
erative liver and tumour volumes were meticulously analysed.
The extent of the right liver resections was similar between the
three groups. Of note, the assessment of the percentage of post-
operative functional liver volume (i.e. taking into account
tumour volume) confirmed that patients in the three groups
underwent the same loss in functional liver volume.
The reasons why liver function per unit of liver volume is
better after PVE are not completely elucidated, but it is likely
that the PVE-primed liver can manage sequentially the tasks
that stress simultaneously the residual liver after an unprepared
hepatectomy. Ninomiya et al.30 showed that the deceleration of
the regenerative response improved the outcome of rats after a
massive hepatectomy. Based on this work, it can be hypothe-
sized that, immediately after a liver resection, the hepatocytes
face two competing tasks: proliferating and metabolizing; these
tasks stress the capacities of the cellular machinery and are
Table 3 Liver volumes of patients with and without portal vein embolization and liver donors
Variable PVE (n = 28) No PVE
(n = 53)
LD (n = 17) P-valuea (PVE
versus no PVE)
P-valuea (PVE
versus LD)
Total liver volume (cc) (mean  SD) 1654 (460) 1622 () 1399 (174) 0.529 0.011
Total liver volume/body weight (%) (mean  SD) 2.26 (0.42) 2.44 (0.67) 2.14 (0.25) 0.376 0.691
Tumor volume (mean  SD) 106 (153) 189 (269) 0 (0) 0.492 <0.001
Functional liver volume (cc) (mean  SD)
(Total liver volume minus tumor volume)
1547 (492) 1434 (231) 1399 (174) 0.480 0.337
Functional liver volume/body weight (%) (mean  SD) 2.10 (0.42) 2.14 (0.39) 2.14 (0.25) 0.912 0.482
Resected liver (g) (mean  SD) 834 (301) 832 (245) 687 (123) 0.757 0.065
Resected liver/body weight (%) (mean  SD) 1.16 (0.36) 1.23 (0.47) 1.06 (0.16) 0.538 0.598
Functional liver resected (cc) (mean  SD)
(Resected liver minus tumor volume)
706 (267) 664 (228) 667 (119) 0.949 0.999
Functional liver resected/body weight (%) (mean  SD) 0.97 (0.25) 0.96 (0.35) 1.02 (0.15) 0.670 0.145
Remnant liver volume (cc) (mean  SD) 850 (323) 818 (309) 711 (104) 0.558 0.132
Remnant liver volume/body weight (%) (mean  SD) 1.15 (0.34) 1.23 (0.38) 1.10 (0.19) 0.873 0.436
Remnant liver volume/Functional liver volume (%)
(mean  SD)
53.8 (11.3) 56.2 (13.8) 51.7 (5.8) 0.999 0.327
PVE, Portal vein embolization; LD, liver donor; cc, cubic centimeter; SD, standard deviation.
aP-values were calculated using the Mann–Whitney U-Test.
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thus in competition. This hypothesis is supported by studies in
which liver regeneration correlates negatively with metabolic
function.31–34 Also, during the days after a liver resection, the
new hepatocytes do not have the corresponding sinusoidal cells
needed to constitute a working functional unit. Ding et al.35
confirmed the critical role of sinusoidal cells and transcription
factor Id1 (Vascular Endothelial Growth Factor dependent) in
liver regeneration. An indication of the fundamental role of
sinusoidal cells during liver regeneration is suggested by the
remarkable ability of regeneration seen in patients with fulmi-
nant A hepatitis,36 in whom the sinusoidal scaffold is intact,
despite a loss of 90% of hepatocytes.37 Also consistent with this
double stress hypothesis, portocaval shunt, by reducing the
portal hypertension signals leading to hepatocyte replication,
reduces overall mortality in small-for-size syndrome.38,39 In
summary, it may be hypothesized that PVE triggers liver regen-
eration (both of hepatocytes and of sinusoidal cells) at a time
when metabolic demand is low (i.e. 6 weeks before the hepate-
ctomy), leaving the cellular machinery free to accomplish the
metabolic tasks immediately after the major liver resection.
(a) (b)
(c)
(e)
(d)
1 2 3 4 5 6 7 8 9 10
0
20
40
60
80
100
PVE (N = 28)
No PVE (N = 53)
Liver donors (N = 17)
Post-operative day
Fa
ct
or
 V
 (%
)
* PVE vs. no PVE (D2: P = 0.010)
† PVE vs. liver donors (D1: P = 0.001, D2: P = 0.005)
P-values were calculated using the Mann–Whitney U Test 
*
†
†
Factor V
0 1 2 3 4 5 6 7 8 9 10
0
20
40
60
80
100
PVE (N = 28)
Liver donors (N = 17)
No PVE (N = 53)
Post-operative day
Pr
ot
hr
om
bi
n 
ra
tio
 (%
)
Prothrombin ratio
* PVE vs. no PVE (D2: P = 0.012)
† PVE vs. liver donors (D1: P = 0.006, D2: P = 0.021)
P-values were calculated using the Mann–Whitney U Test 
*
†
†
0 1 2 3 4 5 6 7 8 9 10
0
20
40
60
80 PVE (N = 28)
No PVE (N = 53)
Liver donors (N = 17)
Post-operative day
B
ili
ru
bi
ne
 (µ
m
ol
/l)
*
*
* *
* PVE vs. no PVE (D1: P = 0.035, D2: P = 0.002, D3: P < 0.001, D4: P = 0.042)
† PVE vs. liver donors (D1: P = 0.009, D2: P = 0.003, D3: P = 0.001, D4: P < 0.001, D5: P = 0.001)
P-values were calculated using the Mann–Whitney U Test 
†
†
†
† †
Bilirubine
0 1 2 3 4 5 6 7 8 9 10
0
200
400
600
800
1000
PVE (N = 28)
Liver donors (N = 17)
No PVE (N = 53)
Post-operative day
A
LT
 (U
I)
ALT
* PVE vs. no PVE (D7: P = 0.016)
† PVE vs. liver donors (D1: P < 0.001, D2: P = 0.034, D7: P = 0.011) 
P-values were calculated using the Mann–Whitney U Test 
*
†
†
†
0 1 2 3 4 5 6 7 8 9 10
0
200
400
600
800
1000
PVE (N = 28)
Liver donors (N = 17)
No PVE (N = 53)
Post-operative day
A
ST
 (U
I)
AST
* PVE vs. no PVE (D5: P = 0.022, D7: P = 0.002)
† PVE vs. liver donors (D1: P < 0.001, D2: P = 0.004, D5: P = 0.015, D6: P = 0.001, D7: P = 0.002)  
P-values were calculated using the Mann–Whitney U Test 
*
†
†
†
† †*
Figure 1 Post-operative serum factor V (a, prothrombin ratio (b), bilirubin (c), alanine transaminase (ALT) (d) and aspartate transaminase
(AST) (e) levels for patients with portal vein embolization (PVE) (blue dots), without PVE (black triangles) and liver donors (LD) (red
squares). The mean values are reported from day 0 (before the surgery, except for factor V) to post-operative day 10. Values are
expressed as mean  SD. * and † refers to a significant P value comparing PVE versus no PVE and PVE versus liver donors,
respectively. P-values were calculated using the Mann–Whitney U-Test
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This study has some limitations. First, a retrospective study
does not allow definitive conclusions. A prospective random-
ized study would allow the assessment of the impact of PVE
on liver function (as opposed to volume) in greater details.
However, PVE is now a fully accepted procedure for patient’s
preparation before a right hepatectomy, and because random-
ization would be difficult to justify. Another limitation is that
the methods to estimate liver function did not include other
more subtle techniques such as indocyanine green, xylocaine,
galactose retention tests or the LiMAx test40 because they were
not available in this retrospective setting. The fact that we had
access only to standard laboratory values is one limitation of
this study. Nevertheless, factor V and the prothrombin ratio,
as well as bilirubin blood levels, are a reliable indicator of liver
function as supported by the present results and by the litera-
ture: they predict post-operative liver failure and mortality,
and at present no valid and consensual substitutes are available
in clinical practice.13 Young living donors with healthy par-
enchyma were used as a second control group. This compar-
ison is of interest because liver donors are the best controls to
analyse liver function without the effect of any prior regenera-
tion stimuli before a hepatectomy. This comparison confirmed
the differences observed between the PVE group and the no
PVE group, namely that the same volume of primed PVE liver
shows better liver function immediately after the operation.
This despite the fact that important biases, such as a younger
age, lower weight, lower ASA score, smaller operative blood
losses and the absence of chemotherapy or of chemotherapy-
associated lesions, all favoured the living donors group.14,41
Another clinically relevant difference between the groups was
that patients with PVE lost more blood and needed more
transfusions than the patients in the no PVE groups. Potential
explanations for this difference are that the transection surface
is larger, and that the interruption of portal vein flow into the
right liver slightly increases the blood flow to the left liver fur-
ther causing more bleeding during surgery after PVE, as previ-
ously reported by others.42 It was also observed that sinusoidal
obstruction syndrome was more frequent in PVE patients. This
is most likely as a result of a combination of two factors: the
interruption of the portal vein flow and the higher prevalence
P-values were calculated using the Mann–Whitney U Test 
PVE
No PVE
Liver donors
PVE
No PVE
Liver donors
PVE No PVE LD
0.1
1
10
100
(a) (b)
(c)
P = 0.003
P = 0.002
B
ili
ru
bi
n-
da
y-
3 
in
de
x 
(lo
g1
0 
sc
al
e)
0.0 0.5 1.0 1.5 2.0 2.5 3.0
0
20
40
60
80
100
Remnant liver volume/body weight
B
ili
ru
bi
n 
le
ve
ls
 a
t d
ay
 3
 (µ
m
ol
/l)
P-values were calculated using the Gehan-Breslow-Wilcoxon Test
P = 0.013 (PVE vs. no PVE)
P = 0.004 (PVE vs. LD)
0 2 4 6 8 10
0
20
40
60
80
100
PVE
Liver donors
No PVE
Post-operative day
Pe
r c
en
t w
ith
 s
er
um
bi
lir
ub
in
 <
25
 µ
m
ol
/l
Figure 2 (a) Post-operative liver function index (Bilirubin at day 3 9 Patient’s weight/Remnant Liver Volume). P-values were calculated
using the Mann–Whitney U-Test. (b) Bilirubin levels at day 3 as a function of the Remnant Liver Volume to Body Weight ratios. (c)
Kaplan–Meier estimates representing the time to bilirubin normalization (i.e. ≤25 lmol/l). P-values were calculated using the Gehan–
Breslow–Wilcoxon Test. Patients are represented as follow: portal vein embolization (PVE) (blue dots), no portal vein embolization (PVE)
(red squares) and liver donors (LD) (black triangles)
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of extended chemotherapy in the PVE group compared with
the no PVE groups. Thus, the benefit brought by PVE, namely
the lower bilirubin values and increased factor V, should be
balanced with potential additional risks such as an increased
intra-operative blood loss and the higher occurrence of sinu-
soidal obstruction syndrome in patients with PVE. Further, the
possibility of non/malperfused areas of the liver could add
some variability in the measurement of remnant functional
volume and post-operative liver function.
Other investigators addressed the question of the possible
increase in liver function after PVE with different techniques,
estimating liver function before liver resection with 99mTc-
labelled galactosyl–human serum albumin scintigraphy,7–9 99m
Tc-labelled mebrofenin hepatobiliary scintigraphy6 and the
indocyanine-green clearance test.43 Others suggested that portal
vein occlusion together with in situ splitting allow an extended
right hepatic resection in small-for-size settings (ALPPS, Asso-
ciated Liver Partition and Portal vein ligation for Staged hepa-
tectomy).44–46 Farges et al.5 prospectively compared post- right
hepatectomy outcomes in 27 patients with and 28 without
PVE in a non-randomized study. Similar to this study, PVE
improved the post-operative liver function in patients but the
advantage was significant only in patients with the chronic
liver disease. In this investigation, additional evidence is pro-
vided by quantifying the increase in liver function per unit of
liver volume, and showed that this increase is also present in
patients without underlying liver disease. Furthermore, recent
studies showed that PVE combined with coiling led to an
increased liver hypertrophy47 and this improvement might
strengthen the significance of the present findings.
These results suggest that, in patients who have undergone
PVE, the immediate post-operative liver function per unit of
volume (the specific liver function) is improved compared with
patients who undergo hepatectomy on an unprepared liver.
The volume criteria that would preclude safe liver resection in
the absence of PVE may be revaluated in future prospective
studies.
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